Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.46 |
| ▸ | PDE4A | P27815 | 12/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.46 |
| ▸ | MET | P08581 | 6/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6842157 | 0.96 | PDE4D (0.50) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL6844014 | 0.91 | PDE4D (0.57) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL6842429 | 0.89 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL7798643 | 0.89 | PDE4D (0.44) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL6842919 | 0.89 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL6837186 | 0.88 | PDE4D (0.44) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL7792850 | 0.88 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL6841893 | 0.87 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL6842264 | 0.87 | PDE4D (0.44) | PDE4DPDE4APDE4BPDE4CMET | |
| SCHEMBL6841769 | 0.86 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4CMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | PDE4D 12/4885PDE4A 1/4885PDE4B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.